Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TSC-203-A0201 |
Synonyms | |
Therapy Description |
TSC-203-A0201 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the PRAME antigen presented on HLA-A*02:01, which potentially induces proliferation of CD4+ and CD8+ T lymphocytes and enhances antitumor immune response (Cancer Immunol Res (2024) 12 (10_Supplement): B041). |